Skip to main content
. 2011 Sep 13;83(11):2008–2017. doi: 10.1002/jmv.22221

Table IIb.

Co‐Occurrence of Respiratory Viruses in the Nasopharynx of Healthy Children

Healthy children, N = 66 N With HboV With PyV With PIV With RSV With HadV With EV With CoV With HMV With Flu
Rhinovirus positive 28 7 (25.0) 5 (17.9) 2 (7.1) 2 (7.1) 2 (7.1) 1 (3.6) 1 (3.6) 1 (3.6)
Rhinovirus negative 38 6 (15.8) 5 (13.2) 4 (10.5) 4 (10.5) 2 (5.3) 4 (10.5) 3 (7.9) 0 (0.0)
 P‐value 0.4 0.6 0.6 0.6 0.8 0.3 0.5 0.2
Bocavirus positive 13 3 (23.1) 2 (15.4) 3 (23.0) 0 (0.0) 1 (7.7) 2 (15.4) 0 (0.0)
Bocavirus negative 53 7 (13.2) 4 (7.5) 3 (5.7) 4 (7.5) 4 (7.5) 2 (3.8) 1 (1.9)
 P‐value 0.4 0.4 0.05 0.3 1.0 0.1 0.6
Polyomavirus positive 10 1 (10.0) 0 (0.0) 1 (10.0) 1 (10.0) 1 (10.0) 0 (0.0)
Polyomavirus negative 56 5 (8.9) 6 (10.7) 3 (5.4) 4 (7.1) 3 (5.4) 1 (1.8)
 P‐value 0.9 0.3 0.6 0.8 0.6 0.7
Parainfluenzavirus positive 6 1 (16.7) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0)
Parainfluenzavirus negative 60 5 (8.3) 4 (6.7) 4 (6.7) 4 (6.7) 1 (1.7)
 P‐value 0.5 0.5 0.4 0.5 0.8
RSV positive 6 0 (0.0) 2 (33.3) 0 (0.0) 0 (0.0)
RSV negative 60 4 (6.7) 3 (5.0) 4 (6.7) 1 (1.7)
 P‐value 0.5 0.01 0.5 0.8
Adenovirus positive 4 1 (25.0) 0 (0.0) 0 (0.0)
Adenovirus negative 62 4 (6.5) 4 (6.5) 1 (1.6)
 P‐value 0.2 0.6 0.8
Enterovirus positive 5 0 (0.0) 0 (0.0)
Enterovirus negative 61 4 (6.6) 1 (1.6)
 P‐value 0.6 0.8
Coronavirus positive 4 0 (0.0)
Coronavirus negative 62 1 (1.6)
 P‐value 0.8
Human metapneumovirus positive 1
Human metapneumovirus negative 65
 P‐value

HBoV, human bocavirus; PyV, polyomavirus; PIV, parainfluenza virus; RSV, respiratory syncytial virus; HAdV, human adenovirus; EV, enterovirus; CoV, coronavirus; HMV, human metapneumovirus; Flu, influenza virus.

Number and percentage (between brackets) of samples in which viruses were detected. P‐value (in bold when significant) as determined by Pearson chi‐square analyses. Percentage calculated as percentage of the virus positive and virus negative value.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.